Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Nov 10 - Nov 15
Similar content being viewed by others Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) (formerly non-alcoholic fatty liver disease (NAFLD)) is characterised by fat accumulation within the liver parenchyma thereby making it one of the steatotic liver diseases (SLD)
Several developments in 20252026 have changed this picture
Amplitude O (Effect of Efpeglenatide on Cardiovascular Outcomes) revealed that patients with type 2 DM and CVD or kidney disease receiving once weekly efpeglenatide had a 27% lower incidence of the primary composite outcome and 32% lower risk of a composite renal outcome event compared to those receiving placebo [17]
The top 10 causes of death
US$ 23.87
US$ 26.72
US$ 24.17
US$ 25.90
US$ 28.58
